At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
Ifetroban Sodium +1 moredrug
Likely dose
Ifetroban Sodium 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Thromboxane Receptor Antagonist to Block the Effects of Non-Platelet Thromboxane Generation and Improve Endothelial Function (TRAP) Trial
In Brief
A Phase 2 clinical trial evaluating Ifetroban Sodium and Placebo for Cardiovascular Diseases and Vascular Dilation. Completed, enrolled 57 participants across 1 site.
Detailed Summary
This study evaluates whether addition of the thromboxane receptor antagonist to chronic aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation in patients with established cardiovascular disease. Half of participants will receive ifetroban and the other half will receive matching placebo for the 4 week study period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Vascular Dilation
CountriesUnited States
CollaboratorsAmerican Heart Association, Cumberland Pharmaceuticals
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartSep 2019
Primary CompletionNov 2022
Study CompletionNov 2022
TodayJul 2026
First PostedMay 24, 2019
Enrollment StartSep 20, 2019
Primary CompletionNov 7, 2022
Study CompletionNov 15, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.1 years ago
Interventions
Ifetroban Sodiumdrug
Ifetroban sodium 250 mg capsule once daily for 4 weeks
Placebodrug
Placebo arm to match Ifetroban Sodium once daily for 4 weeks.